ReviewThe oncologist2024
High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions.
Review in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- Circulating Tumor Function: A Systems Biology Framework for Liquid Biopsy in Genitourinary Cancers.Genes · 2026Review
- Tumor-informed ctDNA surveillance after radical nephrectomy and level IV IVC thrombectomy for clear cell renal cell carcinoma: Early detection of molecular residual disease.Urology case reports · 2026Article
- Artificial intelligence and multi-omics integration in liquid biopsy for genitourinary cancers: a systematic scoping review.International urology and nephrology · 2026Article
- Preventive Strategies and Biomarkers in Male Reproductive Health from Multidisciplinary Perspective: Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.medRxiv : the preprint server for health sciences · 2026Article
- Post-IMvigor011 Era: CtDNA-Guided Postoperative Adjuvant Treatment Stratification in Muscle-Invasive Bladder Cancer.Cancer management and research · 2026Review
- Management and Treatment Strategies for Upper Tract Urothelial Carcinoma: Current Insights.Research and reports in urology · 2026Review
- Liquid biopsy in genitourinary cancers: Diagnostic and prognostic implications.World journal of clinical oncology · 2025Review
- Monitoring and Assessment of Circulating Tumor DNA in Cancers Using Ultrarapid Sensitivity as an Innovative Practice.Health science reports · 2025Article
- Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients.Scientific reports · 2025Article
- Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.Discover oncology · 2025Review
- Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.JCO precision oncology · 2025Article
- Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors.Journal of clinical medicine · 2024Review
- Adjuvant immunotherapy for muscle-invasive urothelial carcinoma: Considerations for targeting patients.Bladder cancer (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the recent decade, analysis of circulating tumor DNA (ctDNA) has improved cancer care by allowing for rapid detection of actionable molecular targets. A new generation of circulating DNA tests is now becoming available commercially. These tests are characterized by a superior limit of detection of 0.01% vaF or better, allowing for the detection of radiologically occult molecular residual disease (MRD). MRD tests have the potential to revolutionize neoadjuvant and adjuvant treatment. In addition, these tests can be used as tumor markers to assess disease response. We reviewed the current evidence for the use of high-sensitivity MRD assays with particular focus on the genitourinary tumors. Multiple studies have now been reported in urothelial, renal, and recently testicular carcinoma. We find that the sensitivity varies across tumor types in the adjuvant setting and may reach a high of 100% in urothelial cancer. Specificity in tumor-informed MRD appears to be preserved across tumor types (98%-100%). Several trials are now prospectively validating MRD testing in biomarker integral studies, mainly in urothelial carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.